Abstract
Chlorogenic acid (5-O-caffeoylquinic acid, CA), a phenolic compound found ubiquitously in plants, has antidiabetic effect in diabetic animal models. In this study, we investigated the inhibitory effect of CA on diabetic cataractogenesis. We evaluated the aldose reductase (AR) activity during cataract development in 50% galactose-fed rats, an animal model of sugar cataract. Galactose-fed rats were treated orally with CA (10 and 50 mg/kg body weight) once a day for 2 weeks. In vehicle-treated galactose-fed rats, lens opacity was increased, and lens fiber swelling and membrane rupture were observed. In addition, AR protein was highly expressed in lens epithelial cells and lens cortical fibers of galactose-fed rats. However, CA inhibited the rat AR activity in vitro, and the administration of CA prevented the development of sugar cataract through the inhibition of AR activity. These observations suggest that CA is useful for the treatment of sugar cataract.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Akagi, Y., Kador, P. F., and Kinoshita, J. H., Immunohistochemical localization for aldose reductase in diabetic lenses. Invest. Ophthalmol. Vis. Sci., 28, 163–167 (1987).
Andrade-Cetto, A. and Wiedenfeld, H., Hypoglycemic effect of Cecropia obtusifolia on streptozotocin diabetic rats. J. Ethnopharmacol., 78, 145–149 (2001).
Ao, S., Shingu, Y., Kikuchi, C., Takano, Y., Nomura, K., Fujiwara, T., Ohkubo, Y., Notsu, Y., and Yamaguchi, I., Characterization of a novel aldose reductase inhibitor, FR74366, and its effects on diabetic cataract and neuropathy in the rat. Metabolism, 40, 77–87 (1991).
Costantino, L., Rastelli, G., Vianello, P., Cignarella, G., and Barlocco, D., Diabetes complications and their potential prevention: aldose reductase inhibition and other approaches. Med. Res. Rev., 19, 3–23 (1999).
Harries, W., Tsui, J., and Unakar, N. J., Ultrastructural cytochemistry: effect of Sorbinil on arylsulfatases in cataractous lenses. Curr. Eye Res., 4, 657–666 (1985).
Herrera-Arellano, A., Aguilar-Santamaría, L., García-Hernández, B., Nicasio-Torres, P., and Tortoriello, J., Clinical trial of Cecropia obtusifolia and Marrubium vulgare leaf extracts on blood glucose and serum lipids in type 2 diabetics. Phytomedicine, 11, 561–566 (2004).
Huang, R., Shi, F., Lei, T., Song, Y., Hughes, C. L., and Liu, G., Effect of the isoflavone genistein against galactoseinduced cataracts in rats. Exp. Biol. Med., 232, 118–125 (2007).
Jung, H. A., Islam, M. D., Kwon, Y. S., Jin, S. E., Son, Y. K., Park, J. J., Sohn, H. S., and Choi, J. S., Extraction and identification of three major aldose reductase inhibitors from Artemisia montana. Food Chem. Toxicol., 49, 376–384 (2011).
Kador, P. F., Inoue, J., Secchi, E. F., Lizak, M. J., Rodriguez, L., Mori, K., Greentree, W., Blessing, K., Lackner, P. A., and Sato, S., Effect of sorbitol dehydrogenase inhibition on sugar cataract formation in galactose-fed and diabetic rats. Exp. Eye Res., 67, 203–208 (1998).
Kim, Y. S., Kim, N. H., Jung, D. H., Jang, D. S., Lee, Y. M., Kim, J. M., and Kim, J. S., Genistein inhibits aldose reductase activity and high glucose-induced TGF-beta2 expression in human lens epithelial cells. Eur. J. Pharmacol., 594, 18–25 (2008).
Kinoshita, J. H., Mechanisms initiating cataract formation. Proctor Lecture. Invest. Ophthalmol., 13, 713–724 (1974).
Kinoshita, J. H., Kador, P., and Catiles, M., Aldose reductase in diabetic cataracts. JAMA, 246, 257–261 (1981).
Kono, Y., Kashine, S., Yoneyama, T., Sakamoto, Y., Matsui, Y., and Shibata, H., Iron chelation by chlorogenic acid as a natural antioxidant. Biosci. Biotechnol. Biochem., 62, 22–27 (1998).
Lee, A. Y., Chung, S. K., and Chung, S. S., Demonstration that polyol accumulation is responsible for diabetic cataract by the use of transgenic mice expressing the aldose reductase gene in the lens. Proc. Natl. Acad. Sci. U. S. A., 92, 2780–2784 (1995).
Liu, G., Hale, G. E., and Hughes, C. L., Galactose metabolism and ovarian toxicity. Reprod. Toxicol., 14, 377–384 (2000).
Lou, M. F., Dickerson, J. E., Jr., Garadi, R., and York, B. M., Jr., Glutathione depletion in the lens of galactosemic and diabetic rats. Exp. Eye Res., 46, 517–530 (1988).
Matsui, T., Nakamura, Y., Ishikawa, H., Matsuura, A., and Kobayashi, F., Pharmacological profiles of a novel aldose reductase inhibitor, SPR-210, and its effects on streptozotocin-induced diabetic rats. Jpn. J. Pharmacol., 64, 115–124 (1994).
Miwa, I., Kanbara, M., Wakazono, H., and Okuda, J., Analysis of sorbitol, galactitol, and myo-inositol in lens and sciatic nerve by high-performance liquid chromatography. Anal. Biochem., 173, 39–44 (1988).
Mizuno, K., Kato, N., Matsubara, A., Nakano, K., and Kurono, M., Effects of a new aldose reductase inhibitor, (2S, 4S)-6-fluoro-2′,5′-dioxospiro[chroman-4,4′-imidazolidine]-2-carboxamide (SNK-860), on the slowing of motor nerve conduction velocity and metabolic abnormalities in the peripheral nerve in acute streptozotocin-induced diabetic rats. Metabolism, 41, 1081–1086 (1992).
Nakai, N., Fujii, Y., Kobashi, K., and Nomura, K., Aldose reductase inhibitors: flavonoids, alkaloids, acetophenones, benzophenones, and spirohydantoins of chroman. Arch. Biochem. Biophys., 239, 491–496 (1985).
Oates, P. J. and Mylari, B. L., Aldose reductase inhibitors: therapeutic implications for diabetic complications. Expert Opin. Investig. Drugs, 8, 2095–2119 (1999).
Obrosova, I. G., Stevens, M. J., and Lang, H. J., Diabetesinduced changes in retinal NAD-redox status: pharmacological modulation and implications for pathogenesis of diabetic retinopathy. Pharmacology, 62, 172–180 (2001).
Patterson, J. W. and Bunting, K. W., Sugar cataracts, polyol levels and lens swelling. Doc. Ophthalmol., 20, 64–72 (1966).
Reddy, V. N., Schwass, D., Chakrapani, B., and Lim, C. P., Biochemical changes associated with the development and reversal of galactose cataracts. Exp. Eye Res., 23, 483–493 (1976).
Rodriguez de Sotillo, D. V. and Hadley, M., Chlorogenic acid modifies plasma and liver concentrations of: cholesterol, triacylglycerol, and minerals in (fa/fa) Zucker rats. J. Nutr. Biochem., 13, 717–726 (2002).
Simard-Duquesne, N., Greselin, E., Dubuc, J., and Dvornik, D., The effects of a new aldose reductase inhibitor (tolrestat) in galactosemic and diabetic rats. Metabolism, 34, 885–892 (1985).
Terashima, H., Hama, K., Yamamoto, R., Tsuboshima, M., Kikkawa, R., Hatanaka, I., and Shigeta, Y., Effects of a new aldose reductase inhibitor on various tissues in vitro. J. Pharmacol. Exp. Ther., 229, 226–230 (1984).
Tomlinson, D. R., Stevens, E. J., and Diemel, L. T., Aldose reductase inhibitors and their potential for the treatment of diabetic complications. Trends Pharmacol. Sci., 15, 293–297 (1994).
Unakar, N. J. and Tsui, J. Y., Inhibition of galactose-induced alterations in ocular lens with sorbinil. Exp. Eye Res., 36, 685–694 (1983).
Unakar, N. J., Harries, W., and Tsui, J., Acid phosphatase II. Cytochemical localization in lenses of normal and galactose-fed rats. Exp. Eye Res., 40, 117–126 (1985).
Author information
Authors and Affiliations
Corresponding author
Additional information
These authors contributed equally to this work.
Rights and permissions
About this article
Cite this article
Kim, CS., Kim, J., Lee, Y.M. et al. Inhibitory effects of chlorogenic acid on aldose reductase activity in vitro and cataractogenesis in galactose-fed rats. Arch. Pharm. Res. 34, 847–852 (2011). https://doi.org/10.1007/s12272-011-0519-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-011-0519-z